Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PNEU-DAY: V114 versus Prevnar 13 followed by PNEUMOVAX 23 in at-risk adults aged 18-49 years
2017-004915-38Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2018
- Modality
- Vaccines & Immunotherapeutics, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pneumococcal disease comparing V114 followed by PNEUMOVAX 23 with Prevnar 13 followed by PNEUMOVAX 23 (2 arms). Primary endpoint: Serotype-specific opsonophagocytic activity geometric mean titers. Started Jul 2018; status: completed.
02
Drugs
pneumococcal 15-valent conjugate vaccinePrevnar 1323-valent pneumococcal polysaccharide vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on 2017-004915-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004915-38.